何玉龙教授，博士生导师
地址：江苏省苏州市工业园区仁爱路199号
苏州大学唐仲英血液学研究中心
电话: -3621(office), -3616 (lab)
Email: heyulong@suda.edu.cn

教育经历1989-1992年 南京农业大学 动物生殖生物学专业 硕士
1996-1999年 英国 剑桥大学 分子生物学专业 博士
工作经历1992-1994年 南京农业大学（参加江苏省委组织的扶贫工作队，江苏省沭阳县）
1994-1996年 南京农业大学 动物科学系 助教/讲师
1996-1996年 英国 剑桥大学 妇产科系（分子生殖生物学研究室） 访问****
1999-2000年 英国 剑桥大学 病理系（分子生殖生物学研究室） 博士后
2000-2005年 芬兰 赫尔辛基大学 Biomedicum Helsinki（分子肿瘤生物学研究室）
博士后/研究员
2005-2011年 南京大学 模式动物研究所 教授
2016-2017年 德国 马谱分子生物医学研究所 访问****
2011- 至 今 苏州大学 唐仲英血液学研究中心 教授
研究领域1.淋巴管与血管生物学
哺乳类动物的淋巴管源于静脉，即在胚胎发育过程中，部分主静脉内皮细胞分化成淋巴管内皮细胞并逐步发育形成淋巴管系统。相对于心血管相关研究，目前对于淋巴管发生、稳态与功能机制的认识较少。本研究小组主要针对受体酪氨酸激酶包括VEGFR3、Tie2及Tie1等基因，制备了多种转基因与基因敲除小鼠模型，用于研究相关信号途径在淋巴管与血管生成、网络稳态维持、瓣膜发生与功能、以及病理性重塑等过程中的作用与机制。
2.肿瘤生物学
肿瘤转移是癌症病人死亡的主要原因，阐述肿瘤转移的机制具有重要的科学意义与临床价值。利用遗传改造小鼠模型，包括针对受体酪氨酸激酶的条件性基因敲除，结合生物发光体内成像系统及重组病毒载体介导的基因治疗，系统分析肿瘤扩散与转移灶建立过程的分子与细胞生物学机制，并筛选肿瘤组织中淋巴管与血管的特异性分子标志物，为建立肿瘤早期诊断的方法及研制抗肿瘤淋巴管与血管生长的新方法提供实验依据。
研究人员李秀娟 博士，研究员, 博士生导师
Email: lixiujuan@suda.edu.cn，xiujuanli@aliyun.com
长期从事血管生成和血管通透性方面的研究，在血管生成和血管通透性信号通路及相关疾病尤其是肿瘤方面积累了丰富的经验。研究的总体目标是寻求针对血管通透性相关疾病的靶点从而进行治疗干预。迄今为止，以第一作者/共同第一作者, 通讯作者/共同通讯作者在Nature communications (IF 12.12), The Journal of experimental medicine( IF 13.21)，Blood (IF 10.43) , Stem cells( IF 8.28), International Journal of cancer( IF 5.15), Frontiers in Physiology (IF 3.37) 等学术期刊发表20余篇SCI论文。(李秀娟博士个人简历)







曹旭东 博士（待授），助理研究员
招聘研究人员：副研究员、或助理研究员
（招聘广告：http://rsc.suda.edu.cn/df/4a/c275a57162/page.htm ）
研究生博士研究生: 李桃桃；李笑；刘雪莲；孙志亮
硕士研究生: 张金廷；权梦雪；徐蓓蓓；赵乔蕊

本科生: 王子妍；何月娥；刘佳艺；黄霈赟
代表性成果*corresponging author, #co-first author
1.Bae H, Hong KY, Lee CK, Jang C, Lee SJ, Choe K, Offermanns S, He Y*, Lee HJ, Koh GY*. Angiopoietin-2-integrin α5β1 signaling enhances vascular fatty acid transport and prevents ectopic lipid-induced insulin resistance. Nat Commun. 2020 Jun 12;11(1):2980. doi: 10.1038/s41467-020-16795-4.
2. Haijuan Jiang#, Luqing Zhang#, Xuelian Liu#, Wei Sun, Katsuhiro Kato, Chuankai Chen, Xiao Li, Taotao Li, Zhiliang Sun, Wencan Han, Fujing Zhang, Qi Xiao, Zhongzhou Yang, Junhao Hu, Zhihai Qin, Ralf H. Adams, Xiang Gao, Yulong He*. Angiocrine FSTL1 (Follistatin-Like Protein 1) Insufficiency Leads to Atrial and Venous Wall Fibrosis via SMAD3 Activation. ATVB (Arterioscler Thromb Vasc Biol) 2020.doi：10.1161/ATVBAHA.119.313901.bioRxiv 616623; doi:https://doi.org/10.1101/616623.
3.Hu X, Deng Q, Ma L, Li Q, Chen Y, Liao Y, Zhou F, Zhang C, Shao L, Feng J, He T, Ning W, Kong Y, Huo Y, He A, Liu B, Zhang J, Adams R, He Y, Tang F, Bian X, Luo J. Meningeal lymphatic vessels regulate brain tumor drainage and immunity. Cell Res. 2020 30: 229-243. doi: 10.1038/s41422-020-0287-8.
4. He Y*. Angiopoietins and TIE Receptors in Lymphangiogenesis and Tumor Metastasis. In: Marmé D. (eds) Tumor Angiogenesis- A Key Target for Cancer Therapy. 2019 Springer, Cham. https://link.springer.com/referencework/10.1007/978-3-319-31215-6.
5. Zheng Y; Liu C; Li Y; Jiang H; Yang P; Tang J; Xu Y; Wang H; He Y*. Loss-of-function mutations with circadian rhythm regulator Per1/Per2 lead to premature ovarian insufficiency.Biol Reprod.2019 Apr 1;100(4):1066-1072. doi:10.1093/biolre/ioy245.
6. Lee SJ, Lee CK, Kang S, Park I, Kim YH, Kim SK, Hong SP, Bae H, He Y, Kubota Y, Koh GY. Angiopoietin-2 exacerbates cardiac hypoxia and inflammation after myocardial infarction. J Clin Invest. 2018 Nov 1;128(11):5018-5033. doi: 10.1172/JCI99659. Epub 2018 Oct 8.
7. Li P, Wei G, Cao Y, Deng Q, Han X, Huang X, Huo Y, He Y, Chen L, Luo J. Myosin IIa is critical for cAMP-mediated endothelial secretion of von Willebrand factor. Blood 2018 131:686-698. doi: 10.1182/blood-2017-08-802140. Epub 2017 Dec 5
8. Kim J, Park DY, Bae H, Park DY, Kim D, Lee CK, Song S, Chung TY, Lim DH, Kubota Y, Hong YK, He Y, Augustin HG, Oliver G, Koh GY. Impaired angiopoietin/Tie2 signaling compromises Schlemm's canal integrity and induces glaucoma. J Clin Invest. 2017 Oct 2;127(10):3877-3896. doi: 10.1172/JCI94668. Epub 2017 Sep 18.
9. Park DY, Lee J, Kim J, Kim K, Hong S, Han S, Kubota Y, Augustin HG, Ding L, Kim JW, Kim H, He Y, Adams RH, Koh GY. Plastic roles of pericytes in the blood-retinal barrier. Nat Commun. 2017 May 16;8:15296. doi: 10.1038/ncomms15296.
10. 何玉龙*，朱元贵，李伯良，董尔丹*，淋巴管系统相关研究现状与展望，科学通报，2017，62（10）：1030-1040.
11. Chu M#, Li T#, Shen B, Cao X, Zhong H, Zhang L, Zhou F, Ma W, Jiang H, Xie P, Liu Z, Dong N, Xu Y, Zhao Y, Xu G, Lu P, Luo J, Wu Q, Alitalo K, Koh GY, Adams RH, He Y*. Angiopoietin receptor Tie2 is required for vein specification and maintenance via regulating COUP-TFII. Elife. 2016 Dec 22;5. pii: e21032. doi: 10.7554/eLife.21032.
12. Chen L, Li J, Wang F, Dai C, Wu F, Liu X, Li T, Glauben R, Zhang Y, Nie G, He Y*, Qin Z*. Tie2 Expression on Macrophages Is Required for Blood Vessel Reconstruction and Tumor Relapse after Chemotherapy. Cancer Res. 76(23):6828-6838 (2016).
13. Park JS, Kim IK, Han S, Park I, Kim C, Bae J, Oh SJ, Lee S, Kim JH, Woo DC, He Y, Augustin HG, Kim I, Lee D, Koh GY. Normalization of Tumor Vessels by Tie2 Activation and Ang2 Inhibition Enhances Drug Delivery and Produces a Favorable Tumor Microenvironment. Cancer Cell 30(6):953-967 (2016).
14. Han S, Lee SJ, Kim KE, Lee HS, Oh N, Park I, Ko E, Oh SJ, Lee YS, Kim D, Lee S, Lee DH, Lee KH, Chae SY, Lee JH, Kim SJ, Kim HC, Kim S, Kim SH, Kim C, Nakaoka Y, He Y, Augustin HG, Hu J, Song PH, Kim YI, Kim P, Kim I, Koh GY. Amelioration of sepsis by TIE2 activation-induced vascular protection. Sci Transl Med. 8(335):335ra55 (2016). doi: 10.1126/scitranslmed.aad9260.
15. Shen B#, Shang Z#, Wang B#, Zhang L#, Zhou F#, Li T, Chu M, Jiang H, Wang Y, Qiao T, Zhang J, Sun W, Kong X, He Y*. Genetic dissection of TIE pathway in lymphatic maturation and valve development. ATVB (Arterioscler Thromb Vasc Biol)34:1221-1230 (2014).
16. Zhang Y, Lu Y, Ma L, Cao X, Xiao J, Chen J, Jiao S, Gao Y, Liu C, Duan Z, Li D, He Y, Wei B, Wang H Activation of Vascular Endothelial Growth Factor Receptor-3 in Macrophages Restrains TLR4-NF-κB Signaling and Protects against Endotoxin Shock. Immunity. 40:501-514 (2014).
17. Xiong Y, Hu Z, Han X, Jiang B, Zhang R, Zhang X, Lu Y, Geng C, Li W, He Y, Huo Y, Shibuya M, Luo J. Hypertensive stretch regulates endothelial exocytosis of Weibel-Palade bodies through VEGF receptor 2 signaling pathways. Cell Res 23:820-34 (2013).
18. Li T, Yang J, Zhou Q, He Y*. Molecular Regulation of Lymphangiogenesis in Development and Tumor Microenvironment. Cancer Microenviron. 5:249-260 (2012).
19. Lu Y, Xiong Y, Huo Y, Han J, Yang X, Zhang R, Zhu DS, Klein-Heßling S, Li J, Zhang X, Han X, Li Y, Shen B, He Y, Shibuya M, Feng GS, Luo J. Grb-2-associated binder 1 (Gab1) regulates postnatal ischemic and VEGF-induced angiogenesis through the protein kinase A-endothelial NOS pathway. Proc Natl Acad Sci U S A. 108:2957-2962 (2011).
20. Zhang L#, Zhou F#, Han W#, Shen B, Luo J, Shibuya M, He Y*. VEGFR-3 ligand-binding and kinase activity are required for lymphangiogenesis but not for angiogenesis. Cell Res 20:1319-31 (2010)-Cover paper.
21. Zhou F#, Chang Z#, Zhang L#, Hong Y, Shen B, Wang B, Zhang F, Lu F, Tvorogov D, Alitalo K, Hemmings BA, Yang Z*, He Y*. Akt / Protein Kinase B is required for lymphatic network formation, remodeling and valve development. Am J Pathol 177: 2124-2133 (2010).
22. Holopainen T#, Huang H#, Chen C#, Kim KE, Zhang L, Zhou F, Han W, Li C, Yu J, Wu J, Koh GY, Alitalo K*, He Y*. Angiopoietin-1 overexpression modulates vascular endothelium to facilitate tumor cell dissemination and metastasis establishment. Cancer Res 69:4656-64 (2009).
23. Tammela T#, He Y#, Lyytikkä J, Jeltsch M, Markkanen J, Pajusola K, Ylä-Herttuala S, Alitalo K. Distinct Architecture of Lymphatic Vessels Induced by Chimeric Vascular Endothelial Growth Factor-C/Vascular Endothelial Growth Factor Heparin-Binding Domain Fusion Proteins. Circ Res 100:1468-75 (2007).
24. Wirzenius M, Tammela M, Uutela M, He Y, Odorisio1 T, Zambruno1 G, Nagy JA, Dvorak HF, Ylä-Herttuala S, Shibuya M and Alitalo K. Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting. J Exp Med 204:1431-40 (2007).
25. He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S, Harding T, Jooss K, Takahashi T, Alitalo K. VEGFR-3 mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res 65:4739-46(2005).
26. Lin J, Lalani AS, Harding TC, Gonzalez M, Wu WW, Luan B, Tu GH, Koprivnikar K, VanRoey MJ, He Y, Alitalo K, Jooss K. Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res 65:6901-9 (2005).
27. Bhardwaj S, Roy H, Karpanen T, He Y, Jauhiainen S, Hedman M, Alitalo K, Yla-Herttuala S. Periadventitial angiopoietin-1 gene transfer induces angiogenesis in rabbit carotid arteries. Gene Ther 12:388-94 (2005).
28. He Y#, Rajantie I#, Ilmonen M, Makinen T, Karkkainen MJ, Haiko P, Salven P, Alitalo K. Preexisting lymphatic endothelium but not endothelial progenitor cells are essential for tumor lymphangiogenesis and lymphatic metastasis. Cancer Res 64:3737-40 (2004).
29. He Y, Karpanen T and Alitalo K. Role of lymphangiogenic factors in lymphatic tumor metastasis. Biochim Biophys Acta （BBA Review Cancer） 1654:3-12 (2004).
30. Uutela M, Wirzenius M, Paavonen K, Rajantie I, He Y, Karpanen T, Lohela M, Wiig H, Salven P, Pajusola K, Eriksson U, Alitalo K. PDGF-D induces macrophage recruitment, increased interstitial pressure and blood vessel maturation during angiogenesis. Blood 104:3198-204 (2004).
31. He Y, Kozaki K, Karpanen T, Koshikawa K, Yla-Herttuala S, Takahashi T, Alitalo K. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst 94:785-7 (2002).
32. Charnock-Jones DS,He Yand Smith SK. Angiogenesis and Vascular Endothelial Growth Factor (VEGF) in Reproduction. InThe New Angiotherapy(eds T-P D Fan & E C Kohn), pp.115-128 (2002). Humana Press.
33. Smith SK, He Y, Clark DE, Charnock-Jones DS. Angiogenic growth factor expression in placenta. Semin Perinatol 24, 82-86 (2000).
34. He Y*, Smith SK, Day KA, Clark D, Licence DR, Charnock-Jones DS*. Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity. Mol Endocrinol 13:537-545 (1999).
35. Clark DE, Smith SK, He Y, Day KA, Licence DR, Corps AN, and Charnock-Jones DS. A vascular endothelial growth factor antagonist is produced by the placenta and released into the maternal circulation. Biol Reprod 59:1540-1548 (1998).

招聘研究人员：渴求志同道合者一起探索生命的本质
应聘条件：诚实守信、勤奋好学、真心喜欢科学研究
待遇：衣食无忧